直觉外科 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 For the quarterly period ended March 31, 2026OR For the transition period fromto Commission file number 000-30713 Intuitive Surgical, Inc.(Exact name of Registrant as specified in its Charter) (I.R.S. EmployerIdentification No.) 1020 Kifer RoadSunnyvale, California 94086(Address of principal executive offices) (Zip Code) (408) 523-2100(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock, par value $0.001 per share Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer AcceleratedfilerSmallerreportingcompanyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No The Registrant had 354,162,842 shares of Common Stock, $0.001 par value per share, outstanding as of April15, 2026. PART I. FINANCIAL INFORMATION Item1.Financial Statements (unaudited):Condensed Consolidated Balance Sheets as ofMarch31, 2026andDecember31, 20253Condensed Consolidated Statements of Comprehensive Income for thethreemonths endedMarch31, 2026and20254Condensed Consolidated Statements of Cash Flows for thethreemonths endedMarch31, 2026and20255Notes to Condensed Consolidated Financial Statements6Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item3.Quantitative and Qualitative Disclosures About Market Risk43Item4.Controls and Procedures43 PART II. OTHER INFORMATION Item1.Legal Proceedings44Item1A.Risk Factors44Item2.Unregistered Sales of Equity Securities and Use of Proceeds44Item3.Defaults Upon Senior Securities44Item4.Mine Safety Disclosures44Item5.Other Information44Item6.Exhibits46Signature47 INTUITIVE SURGICAL, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(UNAUDITED) INTUITIVE SURGICAL, INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(UNAUDITED) INTUITIVE SURGICAL, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED) INTUITIVE SURGICAL, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED) In this report, “Intuitive,” the “Company,” “we,” “us,” and “our” refer to Intuitive Surgical, Inc. and its wholly and majority-ownedsubsidiaries. NOTE 1.DESCRIPTION OF THE BUSINESS Intuitive develops, manufactures, and markets da Vincisurgical systems and the Ion endoluminal system. The Company’s products andrelated services enable physicians and healthcare providers to improve the quality of and access to minimally invasive care. The da Vincisurgical system is designed to enable surgeons to perform a wide range of surgical procedures within our targeted general surgery, urologic,gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the first clearedindication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Both systems usesoftware, instruments, and accessories.®® NOTE 2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited Condensed Consolidated Financial Statements (“Financial Statements”) and accompanying notes have been prepared inaccordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulationsof the Securities and Exchange Commission (“SEC”) for interim financial reporting. In the opinion of management, the accompanyingFinancial Statements of Intuitive Surgical, Inc. and its wholly and majority-owned subsi